Approved uses also being limited to certain patients
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
Previous
Previous
FDA’s National Center for Toxicological Research Celebrates Half a Century of Cutting-Edge Research
Next
Next